Your browser is no longer supported. Please, upgrade your browser.
Graybug Vision, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own10.49% Shs Outstand20.98M Perf Week-3.44%
Market Cap112.78M Forward P/E- EPS next Y-3.69 Insider Trans0.00% Shs Float19.84M Perf Month-28.07%
Income-34.70M PEG- EPS next Q-0.44 Inst Own83.00% Short Float5.07% Perf Quarter-79.24%
Sales- P/S- EPS this Y-34.90% Inst Trans1.71% Short Ratio2.00 Perf Half Y-62.70%
Book/sh4.32 P/B1.23 EPS next Y-38.20% ROA- Target Price- Perf Year-
Cash/sh4.49 P/C1.19 EPS next 5Y- ROE- 52W Range5.12 - 37.88 Perf YTD-81.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.93% Beta-
Dividend %- Quick Ratio12.30 Sales past 5Y- Gross Margin- 52W Low4.10% ATR0.92
Employees24 Current Ratio12.30 Sales Q/Q- Oper. Margin- RSI (14)17.65 Volatility9.69% 9.91%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.50 Prev Close5.33
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume501.75K Price5.33
Recom2.20 SMA20-18.28% SMA50-68.02% SMA200-73.80% Volume0 Change0.00%
Mar-10-21Downgrade Wedbush Outperform → Neutral $41 → $8
Mar-09-21Downgrade Piper Sandler Overweight → Neutral $27 → $10
Dec-22-20Initiated Cantor Fitzgerald Overweight $42
Oct-20-20Initiated Wedbush Outperform $41
Oct-20-20Initiated SVB Leerink Outperform $35
Oct-20-20Initiated Piper Sandler Overweight $27
Oct-20-20Initiated Oppenheimer Outperform $41
Oct-20-20Initiated Needham Buy $30
Apr-02-21 07:36PM  
Mar-10-21 04:58PM  
Mar-09-21 11:46AM  
Mar-04-21 05:04PM  
Feb-17-21 07:30AM  
Feb-01-21 07:30AM  
Jan-07-21 07:30AM  
Dec-25-20 02:06AM  
Dec-10-20 04:50PM  
Nov-16-20 04:05PM  
Nov-12-20 04:05PM  
Oct-27-20 07:48PM  
Oct-14-20 04:42AM  
Oct-01-20 11:57AM  
Sep-25-20 02:31PM  
Sep-24-20 08:12PM  
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.